Literature DB >> 30359007

Keto-Enol Tautomerism of Temperature and pH Sensitive Hydrated Curcumin Nanoparticles: Their Role as Nanoreactors and Compatibility with Blood Cells.

Rajpreet Kaur1, Poonam Khullar1, Aabroo Mahal1, Anita Gupta2, Narpinder Singh3, Gurinder Kaur Ahluwalia4, Mandeep Singh Bakshi5.   

Abstract

In order to provide a solution for the poor aqueous solubility and poor bioavailability of curcumin, we present the synthesis and characteristic features of water-soluble curcumin hydrated nanoparticles (CNPs). They are stable and nearly monodisperse in the aqueous phase where the keto form of curcumin self-assembles into spherical CNPs, which are highly sensitive to temperature and pH variations. The CNPs are quite stable up to 40 °C and at neutral pH. A higher temperature range reduces their hydration and makes them unstable, thereby disintegrating them into smaller aggregates. Similarly, a higher pH converts the keto form of CNPs into the enol form by promoting their interparticle fusions driven by hydrogen bonding with a remarkable color change from yellow to bright orange-red which demonstrates their excellent photophysical behavior. The stable keto form CNPs are highly efficient nonreactors for the in situ synthesis of Au, Ag, and Pd NPs which are simultaneously entrapped in curcumin aggregates, thus promoting the metal NP carrying ability of curcumin aggregates. The CNPs also demonstrate their excellent dose-dependent biocompatibility with blood cells. A concentration range up to 5 mM of CNPs is quite safe for their applications in biological systems.

Entities:  

Keywords:  curcumin nanoparticles; fluorophore; hemolysis; keto−enol form of curcumin; metallic nanoparticles

Mesh:

Substances:

Year:  2018        PMID: 30359007     DOI: 10.1021/acs.jafc.8b03893

Source DB:  PubMed          Journal:  J Agric Food Chem        ISSN: 0021-8561            Impact factor:   5.279


  1 in total

1.  Establishment of Fluorescence Sensitization Method for Hydroxysafflor Yellow A.

Authors:  Cao Haiyan; Qin Xiude; Liu Chen; Zhao Xinzhe; M A Yuhui; Zhou Jingna; Liu Yu; G E Shaoqin; Zhang Guowei; Nie Hailiang
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-27       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.